Abstract. The MADIT-II trial showed that in patients with a prior myocardial infarction and ejection fraction ≤0.30, prophylactic implantation of a defibrillator improves survival with a 31% reduction in mortality during an average follow-up of 20 months. Electrophysiologic inducibility was positive in 36% of patients at the time of ICD implantation. Inducibility was associated with increased ICD utilization for ventricular tachycardia during long-term follow-up, and decreased utilization for ventricular fibrillation. These preliminary findings raise questions about the clinical usefulness of electrophysiologic testing as a risk stratifier in patients with advanced left ventricular dysfunction.
Introduction
In 1980, Mirowski and associates reported the first three patients in whom the implanted defibrillator was used in the management of patients with recurrent ventricular tachyarrhythmias refractory to medical therapy [1] . During the 1980s the clinical experience with ICDs progressively increased, but mostly utilized in patients who had been resuscitated from out-of-hospital cardiac arrest or who had documented episodes of recurrent, life-threatening ventricular tachycardias. The 1990s ushered in a number of randomized primary and secondary ICD trials. In 1996, the Multicenter Automatic Defibrillator Implantation Trial (MADIT) was published, and ICD therapy was associated with 54 percent reduction in all cause mortality when compared to conventional therapy in patients who had reduced ejection fraction (EF ≤0.35), non-sustained ventricular tachycardia, and inducible non-suppressible ventricular tachycardia or fibrillation at electrophysiologic study [2] . A study reported in 1999 by the Multicenter Unsustained Tachycardia Trial (MUSTT) confirmed the MADIT findings [3] . Both the MADIT and MUSTT trials were primary prevention studies. During the same period of time, several secondary prevention trials were reported including the Antiarrhythmics Versus Implantable Defibrillators (AVID) study [4] , the Canadian Implantable Defibrillator Study (CIDS) [5] , and the Cardiac Arrest Study Hamburg (CASH) [6] . In each of these studies, ICD therapy was associated with improved survival when compared to antiarrhythmic drug therapy.
The protocol used in most of the aforementioned studies included electrophysiologic testing (EPT) for inducibility. These published studies suggested that electrophysiologic testing should be used to screen and identify patients who would benefit from ICD therapy, but this approach has never been substantiated. In subset analyses from the original MADIT study, we showed that the survival benefit from the ICD was directly related to the severity of the cardiac dysfunction. More specifically, the combinations of the presence of one, two, or three non-invasive factors (EF <0.26, QRS duration on ECG ≥0.12 sec, history of heart failure requiring treatment) were associated with a progressively lower hazard ratio indicating better survival in higher risk patients with ICD therapy [7, 8] .
MADIT-II
When we designed the MADIT-II trial in 1997, we reasoned that in patients with a prior myocardial infarction and advanced left ventricular dysfunction, as manifest by an EF ≤0.30, the scarred myocardium would serve as a substrate for malignant ventricular arrhythmias and electrophysiologic testing would not be needed for risk stratification. The MADIT-II trial randomized 1,232 patients to ICD or conventional therapy. The eligibility and exclusion criteria are presented in Tables 1 and 2 . The hazard ratio for the risk of death from any cause in the defibrillator group compared with the conventional-therapy group was 0.69 (P = 0.016), a finding indicating a 31 percent reduction in the risk of death at any interval with ICD therapy compared to conventional therapy (Figure 1) [9]. Both treatment groups received equivalent and appropriate beta-blocker, angiotensin converting enzyme (ACE) inhibitor, diuretic, digitalis, and aspirin therapy. In an editorial that accompanied the MADIT-II publication, Bigger suggested that improved risk stratification with identification Moss, Daubert and Zareba CEPR 2002; Vol. 6, No. 4 
Electrophysiologic Testing
In MADIT-II, EPT was not an eligibility criterion. However, in patients randomized to ICD therapy, investigators were encouraged to carry out EPT at the time of ICD implantation. It was hypothesized that inducibility would be associated with a greater utilization of ICD therapy for ventricular tachycardia and ventricular fibrillation than would non-inducibility. This electrophysiologic question is Fig. 1 . Kaplan-Meier estimates of the probability of survival in the defibrillator and conventional-therapy groups over time. The difference in survival between the two groups was significant (nominal P = 0.007, by log-rank test) . Reprinted from Ref. [9] with permission. currently under investigation as a high-priority substudy, and some preliminary findings have been reported at the Cardiostim meeting in Nice, France in June 2002. Of the 742 patients randomized to ICD therapy, EPT was carried out in 583 ICD-treated patients. Electrophysiologic inducibility (sustained monomorphic or polymorphic ventricular tachycardia with ≤3 extrastimuli or ventricular fibrillation with ≤2 extrastimuli), was found in 210 of the 583 tested patients (36%); 373 were non-inducible (64%). Using the findings from routine ICD interrogation during follow-up, the frequency of use of appropriate ICD therapy for ventricular tachycardia (antitachycardia pacing or shock) and ventricular fibrillation
